Acute Caffeine Intake and Velocity Metrics

NCT07701395 | Completed

• 1 other identifier: CEIP/2024/5/113
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to determine whether the acute ergogenic effects of caffeine differ according to the velocity metric used to assess strength performance against different relative loads. Thirteen resistance-trained men completed a triple-blind, randomized, placebo-controlled, crossover study. Participants ingested either caffeine (3 mg·kg-1) or a placebo 60 min before performing bench press and back squat exercises at 25%, 50%, 75%, and 90% of one-repetition maximum (1RM). Mean velocity (MV) and mean propulsive velocity (MPV) were simultaneously recorded using a linear position transducer

Conditions

Caffeine and Resistance Exercise

Outcome Measures

Primary Outcomes (1)

• Velocity metrics against different relative loads of one-repetition maximum

  Measuring bar mean velocity (during propulsive and braking phases in m/s) and mean propulsive velocity (m/s of the propulsive phase) displacement of the concentric phase during bench press and back squat exercises at 25%, 50%, 75%, and 90%1RM.

  Through study completion, an average of 3 weeks

Secondary Outcomes (1)

• Adverse effects

  Through study completion, an average of 3 weeks

Study Arms (2)

Caffeine

EXPERIMENTAL

Acute caffeine intake (3 mg·kg-1)

Dietary Supplement: Caffeine

Placebo

PLACEBO COMPARATOR

Acute placebo intake (3 mg·kg-1 of maltodextrin)

Dietary Supplement: Placebo

Interventions

Caffeine DIETARY_SUPPLEMENT

Acute caffeine intake (3 mg·kg-1)

Caffeine

Placebo DIETARY_SUPPLEMENT

Acute placebo intake (3 mg·kg-1 of maltodextrin)

Placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age between 18 and 35 years.
• Body Mass Index (BMI) \< 25 kg/m².
• Resistance-trained individuals (more than 6 months of structured training).
• Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
• Participants must be able to perform the tests described in the following section.

You may not qualify if:

• History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
• Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
• Sedentary habits (less than 150 minutes/week of moderate exercise).
• Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
• Engaging in strenuous exercise within 48 hours prior to the tests.• Failure to replicate the same food intake on both experimental days.
• Consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.

Sponsors & Collaborators

• University of Alcala: lead

Study Sites (1)

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, 28805, Spain

Location

MeSH Terms

Interventions

Caffeine

Intervention Hierarchy (Ancestors)

Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Statistician
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 8, 2026
• First Posted: July 14, 2026
• Study Start: January 1, 2025
• Primary Completion: June 1, 2025
• Study Completion: December 1, 2025
• Last Updated: July 15, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share

Locations

ES (1)